Where does Markus Warmuth work?

Markus Warmuth is Venture Partner at Versant Ventures and M.D., Chief Executive Officer at Monte Rosa Therapeutics.

What check size does Markus Warmuth write?

Markus Warmuth typically writes checks of $100K – $5M.

What companies did Markus Warmuth found?

Markus Warmuth founded Monte Rosa Therapeutics.

Markus Warmuth

InvestorFounder

Venture Partner at Versant Ventures · M.D., Chief Executive Officer at Monte Rosa Therapeutics

Cambridge, Massachusetts

Writes $100K – $5M checks · typically $1.5M

FoundedMonte Rosa Therapeutics

About

Markus Warmuth serves as Chief Executive Officer at Monte Rosa Therapeutics and is a board member at Ventus Therapeutics. He is a physician scientist with experience in drug discovery, translational research, and clinical development across the pharmaceuticals industry.

M.D., Chief Executive Officer at Monte Rosa Therapeutics

Intro paths

→

In turn, Markus can intro founders to Monte Rosa Therapeutics's investors below.

Monte Rosa Therapeutics's investors · 8

Aisling CapitalNew York Amzak HealthNew York Avoro Capital AdvisorsNew York Dimension CapitalSan Francisco · $1M – $10M checks GV (Google Ventures)Mountain View · $250K – $50M checks HBM PartnersZug · $5M – $50M checks New Enterprise Associates (NEA)Menlo Park · $200K – $40M checks · since 2020 Versant VenturesSan Francisco · $250K – $5M checks

Co-founders at Monte Rosa Therapeutics

Sharon TownsonPh.D., Chief Scientific Officer

John CastlePh.D., Chief Data and Information Officer

Filip JankuM.D., Ph.D., Chief Medical Officer

Phil NicksonPh.D., J.D., Chief Business and Legal Officer

Magnus WalterDPhil, Chief Technology Officer

Jennifer ChampouxChief Operating Officer

Andrew FunderburkChief Investor Relations and Strategy Officer

Experience

Ventus TherapeuticsMember Board Of Directorscurrent2021 — present
Monte Rosa TherapeuticsChief Executive Officercurrent2019 — presentBasel Area, Switzerland and Cambridge, MA
Versant VenturesVenture Partnercurrent2019 — presentBoston, Massachusetts
IMV Inc.Independent Board Member2018 — 2023
Third Rock VenturesEntrepreneur In Residence2018 — 2019Boston, Massachusetts
Relay TherapeuticsIndependent Board Member2017 — 2018Cambridge, Massachusetts
H3 BiomedicinePresident and Chief Executive Officer2011 — 2018
H3 BiomedicineChief Scientific Officer2011Cambridge, Massachusetts, USA
Novartis Institutes for BioMedical Research (NIBR)Executive Director and Head of Oncology Drug Dicovery2008 — 2011
Genomics Institute of the Novartis Research FoundationDirector Kinase Platform2002 — 2008
Ludwig-Maximilians Universität MünchenMD1998 — 2002

Education

Ludwig-Maximilians-Universität MünchenMD, Medicine1991 — 1998

Skills & more

Biotechnology46Drug Discovery79Oncology93Cancer38Lifesciences17Molecular Biology26Drug Development58Genomics49High Throughput Screening6Biochemistry20Immunology12Clinical Development18

+12 more

CellCell BiologyIn VitroCell CulturePharmacologyAntibodiesAssay DevelopmentBiomarkersPharmaceutical IndustryTranslational MedicineClinical TrialsCancer Research

From Markus's professional profile.

Deals · 1

Ventus TherapeuticsBoard seat

via Versant Ventures · filed Feb 2022 · $140M raise

Attribution from SEC filings, press coverage, and firm rosters.

Colleagues at Versant Ventures

Alex Mayweg

Managing Director at Versant Ventures

Alicia Levey

Venture Partner at Versant Ventures

Andrew Jefferson

Operating Partner at Versant Ventures

Ariel Kantor

Principal at Versant Ventures

Barbara Lubash

Managing Director at Versant Ventures

Beckie Robertson

Venture Advisor at Intuitive Ventures

Bill Link

Investor at Versant Ventures

Brad Bolzon

Chairman, Managing Director at Versant Ventures

Frequently asked questions

Where does Markus Warmuth work?: Markus Warmuth is Venture Partner at Versant Ventures and M.D., Chief Executive Officer at Monte Rosa Therapeutics.
What check size does Markus Warmuth write?: Markus Warmuth typically writes checks of $100K – $5M.
What companies did Markus Warmuth found?: Markus Warmuth founded Monte Rosa Therapeutics.